Search
Events

United States and Canadian Academy of Pathology 112th Annual Meeting

Roche Diagnostics at USCAP 2023

 

For over 125 years, Roche has been collaborating with pathology and oncology experts around the world to identify, validate, and improve upon clinically relevant biomarkers and efficient instrumentation that can help labs provide the critical answers clinicians and patients need for accurate diagnosis and treatment planning.

 

To achieve our mission, improving the lives of all patients affected by cancer, we look at the needs and challenges healthcare professionals face today by leveraging the power of our unique structure, with pharmaceuticals and diagnostics working together to advance science and develop new therapies.

Join us at USCAP 2023 to learn how labs can leverage digital pathology solutions.
Visit us at booth no. 228

FRa Biology and FOLR1 IHC Scoring

 

Tuesday, March 14, from 12-1 p.m. CT

Exhibit hall room 2

Speaker: S. Michelle Shiller, D.O., PathGroup

 

Introducing the VENTANA FOLR1 (FOLR1-2.1) RxDx Assay, the first FDA-approved immunohistochemistry companion diagnostic test that helps detect the Folate Receptor, α (FOLR1) biomarker in patients with epithelial ovarian cancer (EOC). By testing for FRα expression, labs can identify 35% of patients with EOC that may benefit from a promising FRα targeted therapy – ELAHERETM (mirvetuximab soravtansine). This comprehensive workshop aims to support pathologists with clinical training to better understand FRα biology and scoring of this novel IHC marker for EOC samples.

Related links

HER2-low Assessment: Challenges, Potential Solutions and Clinical Impact

 

Tuesday, March 14, from 5:30-7 p.m. CT

Exhibit hall room 1

Speakers: 

  • Paolo Tarantino, M.D., Dana-Farber Cancer Institute
  • Sunil Badve, M.D., FRCPath, Emory University Hospital School of Medicine
  • Hannah Wen, M.D., Memorial Sloan Kettering Cancer Center

 

Listen to three experts speak about the advances in metastatic-breast-cancer diagnosis and treatment implications. They will cover the evolving classification of HER2 expression and testing in breast cancer, and the challenges and potential solutions for HER2 IHC testing and interpretation. Learn about the pathologist and oncologist point of view as they present challenging case studies for HER2-low assessment that can impact patient care.

Related links

Practical Considerations for Implementing PRAME IHC Testing in Your Laboratory

Wednesday, March 15, from 12-1 p.m. CT

Exhibit hall room 

Speakers: 

  • Sarah Gradecki, M.D., University of Virginia
  • Drazen Jukic, M.D., Georgia Dermatopathology

 

Join us as a panel of dermatopathologists shares their experiences with PRAME testing and implementation in their practices. Listen as they describe what they've learned about the best applications for PRAME testing in dermatopathology, including practical uses and potential pitfalls. They will also review some of their favorite cases to highlight the practice utility of PRAME.

Related links